Rakovina Therapeutics Inc. (7JO0)
XSTU 
Summary
7JO0 Chart
Rakovina Therapeutics Inc. (7JO0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rakovina Therapeutics Inc. ever had a stock split?
Rakovina Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Mads Daugaard Ph.D. CEO | XSTU Exchange | CA75103L1013 ISIN |
| CA Country | - Employees | - Last Dividend | 24 Jun 2025 Last Split | - IPO Date |
Overview
Rakovina Therapeutics Inc. is a biotechnology firm focused on the research and development of innovative cancer treatments. The company specializes in discovering and advancing small-molecule DNA-damage response inhibitors (DDRi), a promising class of therapeutics in the fight against cancer. Initially known as Vincero Capital Corp., Rakovina Therapeutics has rebranded itself in alignment with its dedicated mission to confront cancer through groundbreaking scientific advancements. With its headquarters in Vancouver, Canada, Rakovina Therapeutics is committed to translating cutting-edge research into real-world applications that can potentially transform cancer therapy.
Products and Services
- kt-2000
Kt-2000 represents the next generation of oral targeted small molecule PARP inhibitors. This class of therapeutics is designed to exploit the DNA repair weaknesses in cancer cells, effectively causing the cells to die while minimizing impact on normal cells. As a part of Rakovina Therapeutics’ preclinical product pipeline, kt-2000 aims to offer a targeted and less toxic alternative to traditional cancer treatments.
- kt-3000
Kt-3000 stands out as a bi-functional small-molecule drug candidate, developed to bridge the gap between efficacy and safety in cancer treatment. Its design integrates dual-action mechanisms to enhance the therapeutic window, potentially resulting in superior outcomes for patients suffering from various types of cancer. Rakovina Therapeutics is advancing kt-3000 through preclinical studies to validate its effectiveness and safety profile.
- kt-4000
As part of the innovative spectrum of DDR inhibitors, kt-4000 focuses on directly damaging the DNA of cancer cells. This novel approach seeks to expand the therapeutic arsenal against cancers that have proven resistant to other forms of treatment. By targeting the fundamental mechanisms of cell damage and death, kt-4000 holds the promise of delivering new hope for patients facing the most challenging cancer diagnoses.
